INT151032

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.76
First Reported 2003
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 49
Total Number 49
Disease Relevance 26.32
Pain Relevance 5.71

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Igf1) extracellular region (Igf1)
Anatomy Link Frequency
liver 6
plasma 3
amygdala 2
cerebellum 2
cortex 2
Igf1 (Mus musculus)
Pain Link Frequency Relevance Heat
Somatostatin 424 100.00 Very High Very High Very High
cytokine 79 100.00 Very High Very High Very High
Calcitonin gene-related peptide 10 100.00 Very High Very High Very High
tolerance 95 99.74 Very High Very High Very High
qutenza 8 99.44 Very High Very High Very High
Hippocampus 123 99.28 Very High Very High Very High
Thalamus 72 98.84 Very High Very High Very High
Bioavailability 8 98.60 Very High Very High Very High
dexamethasone 10 98.36 Very High Very High Very High
amygdala 11 98.28 Very High Very High Very High
Disease Link Frequency Relevance Heat
Neurodegenerative Disease 75 99.98 Very High Very High Very High
Death 185 99.76 Very High Very High Very High
Impaired Glucose Tolerance 79 99.74 Very High Very High Very High
Targeted Disruption 457 99.50 Very High Very High Very High
Pulmonary Disease 196 99.40 Very High Very High Very High
Diabetes Mellitus 76 99.02 Very High Very High Very High
Body Weight 68 98.76 Very High Very High Very High
Cancer 512 98.68 Very High Very High Very High
Wound Healing 47 98.60 Very High Very High Very High
Lung Cancer 44 98.44 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The weighted means of normalization of GH and of IGF-I were 54% and 49%, respectively, during treatment with 30 mg lanreotide, whereas during treatment with lanreotide SR 60 mg these values were 60% and 58%.
Localization (normalization) of IGF-I
1) Confidence 0.76 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721386 Disease Relevance 0 Pain Relevance 0
As discussed above, epidemiological studies have clearly demonstrated that controlling GH and IGF-I secretion is the most significant determinant of restoring survival in patients with acromegaly The main goal of treatment of acromegaly is therefore to achieve GH levels of less than 1 ?
Localization (secretion) of IGF-I associated with acromegaly
2) Confidence 0.76 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721386 Disease Relevance 0.70 Pain Relevance 0
Stimulation of sensory neurons by capsaicin increases tissue levels of IGF-I and IGF-I mRNA in various organs via increased calcitonin gene-related peptide (CGRP) release in mice.
Localization (release) of IGF-I in sensory neurons associated with qutenza and calcitonin gene-related peptide
3) Confidence 0.73 Published 2008 Journal Curr. Med. Chem. Section Abstract Doc Link 19075656 Disease Relevance 0.40 Pain Relevance 0.41
Stimulation of sensory neurons by capsaicin increases tissue levels of IGF-I and IGF-I mRNA in various organs via increased calcitonin gene-related peptide (CGRP) release in mice.
Localization (release) of IGF-I in sensory neurons associated with qutenza and calcitonin gene-related peptide
4) Confidence 0.73 Published 2008 Journal Curr. Med. Chem. Section Abstract Doc Link 19075656 Disease Relevance 0.40 Pain Relevance 0.41
Neurogenesis triggered by IGF-1 and GH, i.e., an increased number of neurons, seems more unlikely as neurogenesis is restricted to few brain regions such as the hippocampus.
Localization (triggered) of IGF-1 in neurons associated with hippocampus and neurodegenerative disease
5) Confidence 0.73 Published 2008 Journal Pituitary Section Body Doc Link PMC2712618 Disease Relevance 0.60 Pain Relevance 0.20
GH mediates its effects largely through the increased secretion of insulin-like growth factor 1 (IGF-1) in target tissues including the liver.
Localization (secretion) of IGF-1 in liver
6) Confidence 0.71 Published 2006 Journal PLoS Genetics Section Body Doc Link PMC1698946 Disease Relevance 0.95 Pain Relevance 0
GH mediates its effects largely through the increased secretion of insulin-like growth factor 1 (IGF-1) in target tissues including the liver.
Localization (secretion) of insulin-like growth factor 1 in liver
7) Confidence 0.71 Published 2006 Journal PLoS Genetics Section Body Doc Link PMC1698946 Disease Relevance 0.95 Pain Relevance 0
Circulating IGF-I reflects GH secretion rate and serum concentrations of IGF-I are elevated in all patients with active disease (Melmed 2006).
Localization (secretion) of IGF-I associated with disease
8) Confidence 0.71 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721386 Disease Relevance 0.50 Pain Relevance 0
Factors (not necessarily predictors) associated with tumor shrinkage after primary therapy with somatostatin analogs were post-treatment IGF-I, the age of the patient and the percentage GH decrease (Colao et al 2006a), and essentially confirming previously reported findings (Lucas et al 2003).
Localization (decrease) of IGF-I associated with cancer and somatostatin
9) Confidence 0.71 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721386 Disease Relevance 0.95 Pain Relevance 0.24
The difference between fasting IGF-I and post-lunch IGF-I concentrations in IGT and type-2 diabetes mellitus are directly proportionate, probably indicating nonutilization of IGF-I in post-lunch state.
Localization (nonutilization) of IGF-I associated with diabetes mellitus and tolerance
10) Confidence 0.69 Published 2008 Journal International Journal of Diabetes in Developing Countries Section Body Doc Link PMC2772007 Disease Relevance 0.52 Pain Relevance 0.05
Because of this fact, in patients with insulinoma, a condition characterized by marked hyperinsulinemia, downregulation of insulin receptors induced by elevated plasma insulin was associated with increased abundance of hybrid insulin/IGF-I receptors.[26]
Localization (abundance) of IGF-I in plasma associated with hypoglycemia and hyperinsulinism
11) Confidence 0.69 Published 2008 Journal International Journal of Diabetes in Developing Countries Section Body Doc Link PMC2772007 Disease Relevance 0.40 Pain Relevance 0.03
The ischemic hearts were then reperfused with MK solution alone, MK solution plus IGF-1 (10 ng/ml), or MK solution plus tumor necrosis factor (TNF)-?
Localization (solution) of IGF-1 in hearts associated with necrosis and cancer
12) Confidence 0.68 Published 2003 Journal Crit Care Section Body Doc Link PMC374373 Disease Relevance 0.44 Pain Relevance 0.26
The liver secretes about 70% of the total circulating IGF-I in mice (Sjogren et al 1999).
Localization (secretes) of IGF-I in liver
13) Confidence 0.67 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721386 Disease Relevance 0.68 Pain Relevance 0.03
IGF-I is a peptide synthesized and secreted as a result of GH-signaling, which acts locally in an autocrine or paracrine manner, or systematically as a hormone when secreted by the liver (Le Roith et al 2001).
Localization (secreted) of IGF-I in liver
14) Confidence 0.67 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721386 Disease Relevance 0.37 Pain Relevance 0.03
As a control, relative abundance of IGF-1 and a number of other mRNAs in single mutant XPA, XPCS, and TTD livers was not significantly different from heterozygous controls (unpublished data).
Localization (abundance) of IGF-1 in livers associated with hutchinson-gilford progeria syndrome
15) Confidence 0.67 Published 2006 Journal PLoS Genetics Section Body Doc Link PMC1698946 Disease Relevance 0.70 Pain Relevance 0
Similarly IGF1 and IGF1-receptors are localized predominantly in hippocampus, but also in amygdala, cerebellum and cortex [61].
Localization (localized) of IGF1 in cortex associated with hippocampus and amygdala
16) Confidence 0.66 Published 2008 Journal Behav Brain Funct Section Body Doc Link PMC2531118 Disease Relevance 0.56 Pain Relevance 0.23
Similarly IGF1 and IGF1-receptors are localized predominantly in hippocampus, but also in amygdala, cerebellum and cortex [61].
Localization (localized) of IGF1 in cortex associated with hippocampus and amygdala
17) Confidence 0.66 Published 2008 Journal Behav Brain Funct Section Body Doc Link PMC2531118 Disease Relevance 0.56 Pain Relevance 0.23
Conversely, Igfbp2 binds to extracellular matrix or fibroblasts in the presence of Igf1 or Igf2 and increases their local bioavailability [35,36].
Localization (presence) of Igf1 in extracellular matrix associated with bioavailability
18) Confidence 0.62 Published 2009 Journal Respir Res Section Body Doc Link PMC2770038 Disease Relevance 0.61 Pain Relevance 0.15
g of VEGFxxxb, which was significantly greater than cells treated with IGF-1 alone (0.12 ± 0.02 pg/?
Localization (treated) of IGF-1
19) Confidence 0.61 Published 2010 Journal The Journal of Biological Chemistry Section Body Doc Link PMC2820781 Disease Relevance 0 Pain Relevance 0
In particular, chronic E2 administration has been shown to reduce GH-induced IGF1 increased expression in liver and plasma via a negative feedback mechanism, while acute E2 administration leads to the expected GH-induced IGF1 release [71].
Localization (release) of IGF1 in plasma
20) Confidence 0.58 Published 2008 Journal Behav Brain Funct Section Body Doc Link PMC2531118 Disease Relevance 0.40 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox